EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
Otylia Kowal‐Bielecka(Medical University of Białystok), Marco Matucci‐Cerinic(Azienda Ospedaliero-Universitaria Careggi)
Cited by 615
Related Papers
Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium
|Scientific Reports|2017|48
Proangiogenic effects of soluble α-Klotho on systemic sclerosis dermal microvascular endothelial cells
|Arthritis Research & Therapy|2017|32
Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications
|Journal of Clinical Medicine|2019|20
Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence
|International Journal of Molecular Sciences|2019|19